Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-01
2005-11-01
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S649000
Reexamination Certificate
active
06960577
ABSTRACT:
Methods for treating a patient suffering from or susceptible to treatment resistant major depression comprising administering olanzapine and fluoxetine are disclosed.
REFERENCES:
patent: 5500443 (1996-03-01), Lavielle et al.
patent: 5977099 (1999-11-01), Nickolson
patent: 6130234 (2000-10-01), Bigge et al.
patent: 6147072 (2000-11-01), Bymaster et al.
patent: 0 830 864 (1996-09-01), None
patent: WO 92/00103 (1990-06-01), None
patent: WO 97/33577 (1996-03-01), None
patent: WO 97/35586 (1996-03-01), None
patent: WO 96/24356 (1996-08-01), None
patent: WO 97/23220 (1997-07-01), None
patent: WO 99/61014 (1998-05-01), None
patent: WO 99/62522 (1998-05-01), None
Lindsay Devane C. et al: 1998,Guide to psychotropic drug interactions, 1998, pp. 1-39, XP002102289.
Sherman C.: Atypical antipsychotic as adjunt for depression Tx,Clinical Psychiatry News, vol. 26, No. 8, 1998, pp. 1-2, XP002115885.
Nidecker A.: Olanzapine may soothe schizophrenic's depression,Clinical Psychiatry News, vol. 26, No. 5, 1998, pp. 12-14, XP002115886.
Ananth, Jambur M.D.: Treatment-Resistant Depression, Psychotherapy and Psychosomatics 1998:67, pp. 61-70.
Hungarian Search Report w/Translation.
Sharma V. et al: Treatment of bipolar mixed state with olanzapine,Journal of Psychiatry and Neuroscience, vol. 24, No. 1, Jan. 1999, pp. 40-44, XP002116146.
Oyesami O. et al: Hematologic side effects of psychotropics,Psychosomatics, vol. 40, No. 5, Sep. 1999, pp. 414-421, XP002116147.
Budavari, S., Ed. The Merck Index—1thEdition, Rahway, New Jersey: Merck & Co., Inc., 1989, p. 653, see entry No. 4112 entitled “Fluoxetine”.
97-45747, Miller D D. et al: Effect of antipsychotics on regional cerebral blood flow measured with positron emission tomography, abstract,Neuropsychopharmacology, 17(4), 230-240, 1997.
98-170902, Weisler R. H. et al: Adjunctive use of olanzapine in mood disorders: five case reports, abstract,Annals of Clinical Psychiatry, 9(4), 259-262, Dec. 1997.
97-44995, Devane C. L. et al: Fluvoxamine-induced theophylline toxicity, abstract,American Journal of Psychiatry, 154(9), 1317-1318, 1997.
Andrew A. Nicrenberg, M.D.; Rachel D. McColl, BA.; Management Options for Refractory Depression;The American Journal of Medicine, vol. 101 (Suppl. 6A). Dec. 30, 1996, pp. 455-525.
Maurizio Fava, et al.; Pharmacologic Strategies for Treatment-Resistant Major Depression;Challenges in Clinical Practice: Pharmacologic and Psychosocial Strategies, New York, NY: Guilford Press, 1996, pp. 3-30.
Michael E. Thase, M.D.; A. John Rush, M.D.; Treatment-Resistant Depression:Psychopharmacology: The Fourth Generation of Progress, Raven Press Ltd., New York, 1995, pp. 1081-1097.
Michael E. Thase, M.D.; A. John Rush, M.D.; When at First You Don't Succeed: Sequential Strategies for Antidepressant Nonrespondres;J. Clin. Psychiatry, vol. 58 (suppl 13), 1997, pp. 23-29.
Robert B. Ostroff, M.D.; J. Craig Nelson, M.D.; Risperidone Augmentation of Selective Serotonin Reuptake Inhibitors in Major Depression;J. Clin. Psychiatry, 60:4, Apr. 1999, pp. 256-259.
Maurizio Fava, M.D.; New Approaches to the Treatment of Refractory Depression;J. Clin. Psychiatry 2000:61(suppl 1), pp. 26-32.
Shelton, R.; Tollefson; M. Tohen; W. Buras; K.S. Gannon; S. Stahl; The Study of Olanzapine Plus Fluoxetine in Treatment-Resistant Major Depressive Disorder Without Psychotic Features; 38thNew Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; Boca Raton, Florida; Jun. 10-13, 1998.
J. Craig Nelson, M.D.; Augmentation Strategies with Serotonergic-Noradrenergic Combinations:J. Clin. Psychiatry 1998:59(suppl 5), pp. 65-68.
Nelson, J.C.; The use of antipsychotic drugs in treatment of depression; PMA Publishing, Eds: Zohar J., Belmaker R.H., pp. 131-146, 1987.
Zhang Wei; M.D. et al.; Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex;Neuropsychopharmacology, vol. 23, No. 3, pp. 250-262, 2000.
Guscott, Richard et al.: The Clinical Meaning of Refractory Depression: A Review for the Clinician, Am J. Psychiatry 148:6, Jun. 1991, pp. 695-704.
Thase, Michael et al.: Tricyclics and New Antidepressant Medications: Treatment Options for Treatment-Resistant Depressions, Depression 2:152-168 (1994/1995).
Miller, Del D. et al.: Effect of Antipsychotics on Regional Cerebral Blood Flow Measured with Positron Emission Tomography, Neuropsychopharmacology 1997, vol. 17, No. 4, pp. 230-240.
Bakishi, David, M.D.: Fluoxetine Potentiation by Buspirone: Three Case Histories, Can. J. Psychiatry, vol. 36, Dec. 1991, pp. 749-750.
Ananth, Jambur M.D.: Treatment-Resistant Depression, Psychotherapy and Psychosomatics 1998:67, pp. 61-70.
Eli Lilly and Company
Lentz Nelsen L.
Palmberg Arleen
Spivack Phyllis G.
LandOfFree
Combination therapy for treatment of refractory depression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy for treatment of refractory depression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for treatment of refractory depression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3500235